- Home
- SVII vs ASMB Comparison
SVII vs ASMB Comparison
Compare SVII & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVII
- ASMB
- Stock Information
- Founded
- SVII 2021
- ASMB 2005
- Country
- SVII United States
- ASMB United States
- Employees
- SVII N/A
- ASMB N/A
- Industry
- SVII Blank Checks
- ASMB Biotechnology: Pharmaceutical Preparations
- Sector
- SVII Finance
- ASMB Health Care
- Exchange
- SVII Nasdaq
- ASMB Nasdaq
- Market Cap
- SVII 116.6M
- ASMB 130.2M
- IPO Year
- SVII 2022
- ASMB 2010
- Fundamental
- Price
- SVII $11.71
- ASMB $17.39
- Analyst Decision
- SVII
- ASMB Strong Buy
- Analyst Count
- SVII 0
- ASMB 3
- Target Price
- SVII N/A
- ASMB $33.00
- AVG Volume (30 Days)
- SVII 13.7K
- ASMB 22.2K
- Earning Date
- SVII 01-01-0001
- ASMB 08-07-2025
- Dividend Yield
- SVII N/A
- ASMB N/A
- EPS Growth
- SVII N/A
- ASMB N/A
- EPS
- SVII 0.25
- ASMB N/A
- Revenue
- SVII N/A
- ASMB $32,154,000.00
- Revenue This Year
- SVII N/A
- ASMB $0.04
- Revenue Next Year
- SVII N/A
- ASMB N/A
- P/E Ratio
- SVII $47.09
- ASMB N/A
- Revenue Growth
- SVII N/A
- ASMB 148.33
- 52 Week Low
- SVII $11.06
- ASMB $7.75
- 52 Week High
- SVII $11.90
- ASMB $19.93
- Technical
- Relative Strength Index (RSI)
- SVII 50.67
- ASMB 71.41
- Support Level
- SVII $11.65
- ASMB $15.84
- Resistance Level
- SVII $11.78
- ASMB $17.60
- Average True Range (ATR)
- SVII 0.07
- ASMB 0.93
- MACD
- SVII -0.01
- ASMB 0.01
- Stochastic Oscillator
- SVII 25.53
- ASMB 88.04
About SVII Spring Valley Acquisition Corp. II
Spring Valley Acquisition Corp II is a blank check company.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.